Next 10 |
home / stock / meso / meso articles
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief ...
U.S. stocks were mixed, with the Dow Jones index falling around 90 points on Friday. Shares of Macy’s, Inc. (NYSE:M) rose sharply during Frid...
Mesoblast Limited (NASDAQ: MESO) has witnessed a phenomenal run in the year so far. Shares of MESO have risen a whopping 208.2% year to date a...
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of XPeng Inc. (NYSE:XPEV) rose sharply during ...
U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday'...
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday. Shares of Seritage Growth Properties (NYSE...
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday. Shares of Medifast, Inc. (NYSE:MED) fe...
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily ...
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...